大剂量帕利夫明预防HLA相合无关供者造血干细胞移植后GVHD的1/2期研究
该1/2期试验评估大剂量帕利夫明(180-720 μg/kg)在减低强度预处理后HLA相合无关供者T细胞充足外周血造血干细胞移植中预防严重慢性GVHD的效果,采用3+3设计确定推荐2期剂量为720 μg/kg,该剂量下无患者发生2-4级急性GVHD(0/19),但严重慢性GVHD发生率与历史对照相比未改变。
要点
- 推荐2期剂量为720 μg/kg,于移植前第-7天给药。
- 720 μg/kg剂量下无患者发生2-4级急性GVHD(0/19)。
- 严重慢性GVHD发生率与历史对照相比未改变。
核心结论
- 大剂量帕利夫明联合减低强度预处理是安全的,可能预防急性GVHD,但在本研究中未影响慢性GVHD发生率。
研究设计与样本
- 1/2期试验,采用3+3设计确定推荐2期剂量,随后进入扩展阶段,共31例患者接受HLA相合无关供者T细胞充足外周血造血干细胞移植。
- 所有31例患者接受氟达拉滨/环磷酰胺减低强度预处理,并采用他克莫司、甲氨蝶呤和西罗莫司进行GVHD预防。
主要发现
- 帕利夫明(180-720 μg/kg)于移植前第-7天给药,耐受良好, notable 3/4级不良事件为自限性皮疹和胰腺酶升高。
- 推荐2期剂量为720 μg/kg,该剂量下无患者发生2-4级急性GVHD(0/19)。
- 严重慢性GVHD发生率(主要终点)与历史对照相比未改变。
- 移植后淋巴细胞表型分析提示帕利夫明调节调节性及初始CD4+ T细胞数量。
关键数值与推荐
- 推荐2期剂量为720 μg/kg。
- 720 μg/kg剂量下2-4级急性GVHD发生率为0/19。
局限性
- 严重慢性GVHD发生率与历史对照相比未改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT). Palifermin, a recombinant N-truncated keratinocyte growth factor (KGF), protects epithelial tissues, including the thymus and gut. Although high-dose KGF prevents GVHD in preclinical models, lower doses of palifermin were ineffective in humans. We conducted a phase 1/2 trial evaluating high-dose palifermin for preventing severe chronic GVHD (CGVHD) in matched unrelated donor T-cell replete peripheral blood HCT after reduced-intensity conditioning (RIC). Using a 3+3 design, we determined the recommended phase 2 dose (RP2D), followed by an expansion phase. Palifermin (180-720 μg/kg) was given on day -7 before HCT. All 31 patients received fludarabine/cyclophosphamide RIC with tacrolimus, methotrexate, and sirolimus for GVHD prophylaxis. Palifermin was well tolerated, with self-limiting rash and pancreatic enzyme elevations as notable grade 3/4 adverse events. The RP2D was 720 μg/kg. Remarkably, no patients at this dose developed grade 2 to 4 acute GVHD (AGVHD [0/19]), although severe CGVHD rates (primary end point) remained unchanged compared to historical controls. Posttransplant lymphocyte phenotyping suggests palifermin modulates regulatory and naïve CD4+ T-cell numbers. These findings indicate that high-dose palifermin with RIC is safe and may prevent AGVHD, although it did not affect CGVHD rates in this study. This trial was registered at www.ClinicalTrials.gov as #NCT02356159.
引用
- Schulz E, Curtis LM, Holtzman NG, et al. Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT. Blood. 2025. PMID: 40331908. doi:10.1182/blood.2024028303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。